These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 19285388)
1. Design of novel quinazoline derivatives and related analogues as potent and selective ALK5 inhibitors. Gellibert F; Fouchet MH; Nguyen VL; Wang R; Krysa G; de Gouville AC; Huet S; Dodic N Bioorg Med Chem Lett; 2009 Apr; 19(8):2277-81. PubMed ID: 19285388 [TBL] [Abstract][Full Text] [Related]
2. Pharmacophore modeling and virtual screening for the discovery of new transforming growth factor-beta type I receptor (ALK5) inhibitors. Ren JX; Li LL; Zou J; Yang L; Yang JL; Yang SY Eur J Med Chem; 2009 Nov; 44(11):4259-65. PubMed ID: 19640613 [TBL] [Abstract][Full Text] [Related]
3. Rapid generation of a high quality lead for transforming growth factor-beta (TGF-beta) type I receptor (ALK5). Goldberg FW; Ward RA; Powell SJ; Debreczeni JE; Norman RA; Roberts NJ; Dishington AP; Gingell HJ; Wickson KF; Roberts AL J Med Chem; 2009 Dec; 52(23):7901-5. PubMed ID: 19736928 [TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of 1,2,4-trisubstituted imidazoles and 1,3,5-trisubstituted pyrazoles as inhibitors of transforming growth factor beta type 1 receptor (ALK5). Li X; Wang L; Long L; Xiao J; Hu Y; Li S Bioorg Med Chem Lett; 2009 Aug; 19(16):4868-72. PubMed ID: 19616940 [TBL] [Abstract][Full Text] [Related]
5. Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors. Gellibert F; Woolven J; Fouchet MH; Mathews N; Goodland H; Lovegrove V; Laroze A; Nguyen VL; Sautet S; Wang R; Janson C; Smith W; Krysa G; Boullay V; De Gouville AC; Huet S; Hartley D J Med Chem; 2004 Aug; 47(18):4494-506. PubMed ID: 15317461 [TBL] [Abstract][Full Text] [Related]
6. SM16, an orally active TGF-beta type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model. Fu K; Corbley MJ; Sun L; Friedman JE; Shan F; Papadatos JL; Costa D; Lutterodt F; Sweigard H; Bowes S; Choi M; Boriack-Sjodin PA; Arduini RM; Sun D; Newman MN; Zhang X; Mead JN; Chuaqui CE; Cheung HK; Zhang X; Cornebise M; Carter MB; Josiah S; Singh J; Lee WC; Gill A; Ling LE Arterioscler Thromb Vasc Biol; 2008 Apr; 28(4):665-71. PubMed ID: 18202322 [TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and evaluation of novel 4-thiazolylimidazoles as inhibitors of transforming growth factor-β type I receptor kinase. Amada H; Sekiguchi Y; Ono N; Matsunaga Y; Koami T; Asanuma H; Shiozawa F; Endo M; Ikeda A; Aoki M; Fujimoto N; Wada R; Sato M Bioorg Med Chem Lett; 2012 Mar; 22(5):2024-9. PubMed ID: 22325945 [TBL] [Abstract][Full Text] [Related]
8. Pyrazolone based TGFbetaR1 kinase inhibitors. Guckian K; Carter MB; Lin EY; Choi M; Sun L; Boriack-Sjodin PA; Chuaqui C; Lane B; Cheung K; Ling L; Lee WC Bioorg Med Chem Lett; 2010 Jan; 20(1):326-9. PubMed ID: 19914068 [TBL] [Abstract][Full Text] [Related]
9. Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent. Li HY; McMillen WT; Heap CR; McCann DJ; Yan L; Campbell RM; Mundla SR; King CH; Dierks EA; Anderson BD; Britt KS; Huss KL; Voss MD; Wang Y; Clawson DK; Yingling JM; Sawyer JS J Med Chem; 2008 Apr; 51(7):2302-6. PubMed ID: 18314943 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of 4(5)-(6-methylpyridin-2-yl)imidazoles and -pyrazoles as transforming growth factor-beta type 1 receptor kinase inhibitors. Kim DK; Lee YI; Lee YW; Dewang PM; Sheen YY; Kim YW; Park HJ; Yoo J; Lee HS; Kim YK Bioorg Med Chem; 2010 Jun; 18(12):4459-67. PubMed ID: 20472445 [TBL] [Abstract][Full Text] [Related]
11. Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor. Gellibert F; de Gouville AC; Woolven J; Mathews N; Nguyen VL; Bertho-Ruault C; Patikis A; Grygielko ET; Laping NJ; Huet S J Med Chem; 2006 Apr; 49(7):2210-21. PubMed ID: 16570917 [TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and evaluation of indolinones as inhibitors of the transforming growth factor β receptor I (TGFβRI). Roth GJ; Heckel A; Brandl T; Grauert M; Hoerer S; Kley JT; Schnapp G; Baum P; Mennerich D; Schnapp A; Park JE J Med Chem; 2010 Oct; 53(20):7287-95. PubMed ID: 20919678 [TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of 1-substituted-3(5)-(6-methylpyridin-2-yl)-4-(quinolin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors. Jin CH; Krishnaiah M; Sreenu D; Rao KS; Subrahmanyam VB; Park CY; Son JY; Sheen YY; Kim DK Bioorg Med Chem; 2011 Apr; 19(8):2633-40. PubMed ID: 21435890 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. Sawyer JS; Anderson BD; Beight DW; Campbell RM; Jones ML; Herron DK; Lampe JW; McCowan JR; McMillen WT; Mort N; Parsons S; Smith EC; Vieth M; Weir LC; Yan L; Zhang F; Yingling JM J Med Chem; 2003 Sep; 46(19):3953-6. PubMed ID: 12954047 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of 4(5)-(6-alkylpyridin-2-yl)imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors. Kim DK; Jang Y; Lee HS; Park HJ; Yoo J J Med Chem; 2007 Jun; 50(13):3143-7. PubMed ID: 17552507 [TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of benzenesulfonamide-substituted 4-(6-alkylpyridin-2-yl)-5-(quinoxalin-6-yl)imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors. Kim DK; Jung SH; Lee HS; Dewang PM Eur J Med Chem; 2009 Feb; 44(2):568-76. PubMed ID: 18467006 [TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of 5-(pyridin-2-yl)thiazoles as transforming growth factor-beta type1 receptor kinase inhibitors. Kim DK; Choi JH; An YJ; Lee HS Bioorg Med Chem Lett; 2008 Mar; 18(6):2122-7. PubMed ID: 18262787 [TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and optimization of 7-substituted-pyrazolo[4,3-b]pyridine ALK5 (activin receptor-like kinase 5) inhibitors. Sabat M; Wang H; Scorah N; Lawson JD; Atienza J; Kamran R; Hixon MS; Dougan DR Bioorg Med Chem Lett; 2017 May; 27(9):1955-1961. PubMed ID: 28359790 [TBL] [Abstract][Full Text] [Related]
19. Induction of heart valve lesions by small-molecule ALK5 inhibitors. Anderton MJ; Mellor HR; Bell A; Sadler C; Pass M; Powell S; Steele SJ; Roberts RR; Heier A Toxicol Pathol; 2011 Oct; 39(6):916-24. PubMed ID: 21859884 [TBL] [Abstract][Full Text] [Related]
20. Discovery of pyrido[3,4-g]quinazoline derivatives as CMGC family protein kinase inhibitors: Design, synthesis, inhibitory potency and X-ray co-crystal structure. Esvan YJ; Zeinyeh W; Boibessot T; Nauton L; Théry V; Knapp S; Chaikuad A; Loaëc N; Meijer L; Anizon F; Giraud F; Moreau P Eur J Med Chem; 2016 Aug; 118():170-7. PubMed ID: 27128181 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]